Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues

Drugs

Volumn 58, Issue SUPPL. 3, 1999, Pages 51-56

  Hainsworth, John D ^a,b  

^a CENTENNIAL MEDICAL CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAMOXIFEN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; HEMATOLOGIC DISEASE; HUMAN; KAPOSI SARCOMA; LIVER CELL CARCINOMA; MEDULLOBLASTOMA; NONHODGKIN LYMPHOMA; TESTIS CANCER;

EID: 0033497194     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958003-00008     Document Type: Conference Paper

References (25)

1. Schwartsmann G, Sprinz E, Kromfield M, et al. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy. J Clin Oncol 1997; 15: 2218-24
2. Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi's sarcoma in the elderly: a randomized study of oral etoposide versus vinblastine. Cancer 1994; 74: 2873-8
3. Ashley DM, Meier L, Kerhy T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996; 14: 1922-7
4. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995; 13: 2072-6
5. Wierzbicki R, Ezzat A, Abdel-Warith A, et al. Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC). Ann Oncol 1994; 5: 466-7
6. Cheng AL, Chen YC, Yeh KH, et al. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996; 77: 872-7
7. Hainsworth JD, Erland JB, Kalman LA, et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended schedule etoposide. J Clin Oncol 1997; 15: 2385-94
8. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 1990; 8: 1613-7
9. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-10
10. Martin M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994; 12: 986-91
11. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 1990; 26: 818-21
12. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990; 2 Suppl. 17: 36-9
13. Dombernowsky P, Nissen NI. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP-16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand Section A 1973; 81: 715-24
14. Rivera G, Avery T, Roberts DW. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213. Eur J Cancer 1975: 11: 639-47
15. Stahelin H. Activity of a new glycosidic lignan derivative (VP16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer 1973; 9: 215-21
16. D'Incalci M, Erba E, Vaghi M, et al. In vitro cytotoxicity of VP-16 on primary tumor and metastasis of Lewis lung carcinoma. Eur J Cancer Clin Oncol 1982; 18: 377-80
17. Brindley CJ, Pedley RB, Antoniw P, et al. Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines. Cancer Chemother Pharmacol 1987; 19: 221-5
18. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7: 1330-40
19. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374-7
20. Clark PI, Cottier B. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 1992; 14 Suppl. 19: 36-9
21. Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol 1993; II: 1322-8
22. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic administration of oral etoposide - a phase I trial. J Clin Oncol 1989; 7: 396-401
23. Hainsworth JD, Gray JR, Stroup SL, et al. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung cancer: comparison of sequential phase II trials using different dose intensities. J Clin Oncol 1997; 15: 3464-71
24. deJong RS, Mulder NH, Uges DR, et al. Randomized comparison of oral pharmacokinetics after oral etoposide phosphate and oral etoposide. Br J Cancer 1997; 75: 1660-6
25. Cooper MA, Einhorn LH. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 1995; 13: 1167-9